| Year |
Citation |
Score |
| 2018 |
Kelley MR, Cardarelli RA, Smalley JL, Ollerhead TA, Andrew PM, Brandon NJ, Deeb TZ, Moss SJ. Locally Reducing KCC2 Activity in the Hippocampus is Sufficient to Induce Temporal Lobe Epilepsy. Ebiomedicine. PMID 29884458 DOI: 10.1016/j.ebiom.2018.05.029 |
0.676 |
|
| 2017 |
Moore YE, Kelley MR, Brandon NJ, Deeb TZ, Moss SJ. Seizing Control of KCC2: A New Therapeutic Target for Epilepsy. Trends in Neurosciences. PMID 28803659 DOI: 10.1016/j.tins.2017.06.008 |
0.674 |
|
| 2016 |
Cairns DM, Chwalek K, Moore YE, Kelley MR, Abbott RD, Moss S, Kaplan DL. Expandable and Rapidly Differentiating Human Induced Neural Stem Cell Lines for Multiple Tissue Engineering Applications. Stem Cell Reports. PMID 27569063 DOI: 10.1016/J.Stemcr.2016.07.017 |
0.489 |
|
| 2016 |
Kelley MR, Deeb TZ, Brandon NJ, Dunlop J, Davies PA, Moss SJ. Compromising KCC2 transporter activity enhances the development of continuous seizure activity. Neuropharmacology. PMID 27108931 DOI: 10.1016/j.neuropharm.2016.04.029 |
0.674 |
|
| 2015 |
Sivakumaran S, Cardarelli RA, Maguire J, Kelley MR, Silayeva L, Morrow DH, Mukherjee J, Moore YE, Mather RJ, Duggan ME, Brandon NJ, Dunlop J, Zicha S, Moss SJ, Deeb TZ. Selective Inhibition of KCC2 Leads to Hyperexcitability and Epileptiform Discharges in Hippocampal Slices and In Vivo. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 35: 8291-6. PMID 26019342 DOI: 10.1523/Jneurosci.5205-14.2015 |
0.67 |
|
| 2015 |
Silayeva L, Deeb TZ, Hines RM, Kelley MR, Munoz MB, Lee HH, Brandon NJ, Dunlop J, Maguire J, Davies PA, Moss SJ. KCC2 activity is critical in limiting the onset and severity of status epilepticus. Proceedings of the National Academy of Sciences of the United States of America. 112: 3523-8. PMID 25733865 DOI: 10.1073/Pnas.1415126112 |
0.646 |
|
| Show low-probability matches. |